Genmab — December 2023
-
For os her på PI har Genmab vel været en no-brainer i laang tid så godt at se det også er ved at gå op for nogle af analytikerne. Der har jo i bund og grund ikke været dårligt nyt fra Genmab efter kursen var 3300 og alle analytikerne havde targets over 3000. Den eneste FA ændring er vel den høje rente.
-
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody
CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL) -
or as Abbvie states "This data may support investigating optimized step-up dose in an outpatient setting." https://news.abbvie.com/2023-12-09-New-Data-for-Bispecific-Antibody-Epcoritamab-DuoBody-R-CD3xCD20-Shows-Strong,-Durable-Treatment-Response-for-Patients-with-Difficult-To-Treat-Relapsed-Refractory-R-R-Follicular-Lymphoma-FL?utm_campaign=generic&utm_medium=social&utm_source=TW&utm_content=other&sf270770143=1
-
Godmorgen
-
Breaking new ground in #MultipleMyeloma #research!
@DrOlaLandgren
shares the analysis of the Phase 2 Centaurus Study, shedding light on the efficacy and safety of daratumumab monotherapy in patients with intermediate-risk or high-risk smoldering multiple #myeloma. #ASH23 https://twitter.com/SylvesterCancer/status/1733635907226391029 https://twitter.com/theMMRF/status/1733633272096469063 https://twitter.com/MM_Hub/status/1733651336317620661 -
-
"This real world analysis is important since 80% of these pts wouldn’t have been eligible for the MagesTEC-1 trial" https://twitter.com/Curley_MD/status/1733548449336107277
-
Smoldering multiple myeloma is an early form of multiple myeloma that isn't cancer yet, which usually progresses to active myeloma, but at a slow rate. The jury is still out wether or not you should treat this already at this stage, or wait and see if it actually becomes MM and treat it then.
-
Trials in general exclude a lot of patients based on criteria set by the investigator. This COULD give better results if patient selection is biased. The real world analysis for Teclistamab is of interest as these are patients treated in the real world outside of those trials, so without those stringent exclusion criteria where some patients are not allowed to participate.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind